Genentech Advances Lunsumio in Phase III Follicular Lymphoma
SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Genentech announced that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb)...
B-cell lymphoma
Advertisement
Treeline Partners With Roche to Evaluate TLN-121 in Lymphoma
WATERTOWN, Mass., September 2, 2026 Treeline Biosciences, Inc. announced a clinical trial collaboration and supply agreement with Roche to...
PeproMene Bio CAR-T Therapy Shows Durable Lymphoma Responses
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
BioOra and WZTL Expand Global CAR-T Therapy Rights
WELLINGTON, New Zealand – May 6, 2026 BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) have signed a binding...
Senhwa’s CX-5461 Gains FDA IND Clearance and NCI Support to Advance in MYC-Driven Lymphoma
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
